Horizon Space Acquisition II (NASDAQ: SLBT) finalized its business combination with SL Bio Ltd., with ordinary shares expected to begin trading on Nasdaq on June 15, 2026.

Key Highlights

  • Horizon Space Acquisition II completed its business combination with SL Bio Ltd., forming a new publicly traded entity.
  • Ordinary shares of the combined company are scheduled to commence trading on Nasdaq on June 15, 2026.
  • The transaction was disclosed in a Form 6-K filing with the SEC under the identifier 0001104659-26-073797.
  • SL Bio is based in Taipei, Taiwan, with its principal executive offices located at a facility in the Nangang District.
  • The company’s SEC registration is associated with the file number 43346.

Horizon Space Acquisition II has finalized its merger with SL Bio Ltd., advancing its transition to public trading on the Nasdaq Stock Market. The newly formed entity announced the completion of the business combination on June 12, 2026, with shares expected to begin trading under the existing ticker on June 15.

The transaction was officially reported to the U.S. Securities and Exchange Commission through a Form 6-K filing, identified by the reference 0001104659-26-073797. This filing confirms the merger’s closure and details the company’s upcoming market entry. The combined entity, headquartered in Taipei’s Nangang District, will maintain its primary operations at a facility on Chongyang Road.

The merger reflects a broader trend of biotechnology firms utilizing special purpose acquisition companies (SPACs) to expedite public listings. Horizon Space Acquisition II, a blank-check company, had previously focused on identifying opportunities in the life sciences and biopharmaceutical sectors. The completion of this deal provides the combined entity with access to Nasdaq’s capital markets, which may support future research and development efforts.

Regulatory documents also reference the company’s SEC registration under file number 43346. The entity will submit annual reports via Form 20-F, as outlined in its regulatory disclosures. For investor inquiries, the company’s contact number remains 26516826.

Market analysts will closely monitor the stock’s performance following its Nasdaq debut. The biotech sector has experienced varied outcomes from recent SPAC mergers, with some companies facing challenges in meeting post-listing expectations. SL Bio’s ability to implement its strategic plans will likely shape investor confidence in the months ahead.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.